Update February 2015: We are very proud that we now can patch ...
- adherent human nerve cells
- adherent human cardiac myocytes and
- adherent HEK263 cells
... with our new patch-chip!
Until now, our prototype has proven to analyse the following paramters:
- Single ion channels currents
- Whole cell mode currents
- Action potentials and
of adherent cells.
This is a globally unique milestone on the road to an electrophysiology and a drug development closer to the real human physiology!
We are currently searching for a private investment to co-fund our future GO-BIO Phase-II SME project, starting Q4/2015.
Update April 2014:
GO-BIO Award 2014
PoreGenic won the highly respected GO-Bio Phase II prize of the German Federal Ministry of Research and Education (BMBF) and a grant of + € 2 million! Please click here.
Fig.: The GO-Bio laureates 2014. Seven Phase-I projects and two Phase-II projects were awarded grants. (photo: BIO Deutschland e.V.)
Rationale: PoreGenic's goal is to address a crucial bottle-neck in research, drug discovery and pre-clinical drug development with an Automated Patch Clamp (APC) system for cellular networks. Currently, there are no APC test systems with high throughput capability available that can generate such in vivo-like data.
Applications: PoreGenic identified +15 biopharmaceutical applications that are feasible only with our system: For example, PoreGenic's know-how will allow pharmaceutical companies, CROs and the academic community to screen CNS compounds for their effect on neuronal long-term potentiation, the most fundamental process of neuronal plasticity and learning. This will help fight Alzheimer's, Parkinson's and other neurodegenerative diseases.
Project: The PoreGenic team started to develop its technology in 2009. In 2010, PoreGenic was awarded with the highly respected GO-Bio prize ( € 3.5 million) of the BMBF for its chip-based APC approach.
Company: PoreGenic Biosciences GmbH will spin-off from Rostock University in 2015.